X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition

Stock Information for X4 Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About X4 Pharmaceuticals Inc.

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide 
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.